Clinical Trials Browser

Nasopharyngeal Carcinoma, Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Nasopharyngeal Carcinoma, Neoplasm Metastasis

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma, Stomatitis

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

Nasopharyngeal Carcinoma, Recurrence

Nasopharyngeal Carcinoma, Neoplasm Metastasis

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma, Malnutrition

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma, Lymphoma, Non-Hodgkin, Mesothelioma, Sarcoma, Stomach Neoplasms, Lymphoma, B-Cell

Nasopharyngeal Carcinoma, Head and Neck Neoplasms, Nasopharyngeal Diseases, Nasopharyngeal Neoplasms

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Clinical Trials

A-TRAIN

Combined Anti-IL6R and Anticoagulation Therapy in Advanced NPC Patients

Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC

KSD-101 Therapy for EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial

Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma

Bacterial Decolonization to Prevent Radiation-induced Oral Mucositis

Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Prospective Observational Study to Predict Severe Oral Mucositis Associated With Chemoradiotherapy in Nasopharyngeal Carcinoma Based on Deep Learning

PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy

A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma Treated With Reduced Volume Intensity Modulated Radiation Therapy:10-Year Outcome and Late Toxicity, Quality of Life

Development of a Machine Learning Model for Nasopharyngeal Carcinoma Screening Based on Tongue Imaging

Detection and Biopsy Guidance of Nasopharyngeal Carcinoma Based on Artificial Intelligence and Endoscopic Images

Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma

SG-AAA-II-01

Tranilast as a Radiosensitizer in Reradiation of Nasopharyngeal Carcinoma

PD-1 Inhibitors Plus Chemoradiotherapy for Metastatic Nasopharyngeal Carcinoma: an Open-label Single-arm, Phase II Trial

Magnifying NBI for Occult NPC

A Retrospective Study Reveals the Relationship Between gp42-IgG Epitopes and EBV-associated NPC

Anrotinib and Tirelizumab in First-line Treatment of RM-NPC

Nasopharyngeal Carcinoma Screening in Zhongshan City

Gemcitabine-based Induction Chemotherapy Combined With Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma

Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients

Serial Epstein-Barr Virus DNA Surveillance in Nasopharyngeal Carcinoma Patients

EP-STAR

Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma

Phase Ⅲ Trial of Adjuvant Chemotherapy in Patients With N2-3 Nasopharyngeal Carcinoma

Effect of Hepatectomy on the Prognosis of Patients With Nasopharyngeal Carcinoma Liver Metastases

Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure

CIPN

PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma

Cadonilimab (AK104) in the Treatment of Nasopharyngeal Carcinoma

Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma

Steroid-Eluting Stent Implant for the Treatment of Radiation-Related Sinusitis

Efficacy and Safety of Sintilimab Plus Bevacizumab in Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: An Open-label Phase II Study

CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC

Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC

Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.

The Function of PA, RBP and TRSF in Malnutrition Detecting and Nutritional Status Monitoring for NPC Patients

Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition

A Bidirectional Study in Exploring the Dynamic Changes of Plasma and Urine Metabolites of Nasopharyngeal Carcinoma.

EBV CAR-T Cells for Nasopharyngeal Carcinoma

BGT007 Cell Treatment of Nasopharyngeal Carcinoma

Development and Validation of a Deep Learning System for Nasopharyngeal Carcinoma Using Endoscopic Images

Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas

Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma

Prospective Nasopharyngeal Carcinoma Screening Using Plasma Epstein-Barr Virus DNA Analysis

Development of Intelligent Model for Radioactive Brain Damage of Nasopharyngeal Carcinoma Based on Radio-metabolomics

Elective Level Ib Irradiation in Nasopharyngeal Carcinoma Patients Based on the International Guidelines

Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma